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The survival of motor neurons (SMN) protein is
essential for the biogenesis of small nuclear RNA
(snRNA)-ribonucleoproteins (snRNPs), the major
components of the pre-mRNA splicing machinery.
Though it is ubiquitously expressed, SMN deficiency
causes themotor neurondegenerative disease spinal
muscular atrophy (SMA). We show here that SMN
deficiency, similar to that which occurs in severe
SMA, has unexpected cell type-specific effects on
the repertoire of snRNAs and mRNAs. It alters the
stoichiometry of snRNAs and causes widespread
pre-mRNA splicing defects in numerous transcripts
of diverse genes, preferentially those containing
a large number of introns, in SMN-deficient mouse
tissues. These findings reveal a key role for the SMN
complex in RNA metabolism and in splicing regula-
tion and indicate that SMA is a general splicing
disease that is not restricted to motor neurons.
INTRODUCTION
The survival of motor neurons (SMN) protein is part of a large
multiprotein complex (the SMN complex) that also contains at
least seven additional proteins, termed Gemins2–8 (Baccon
et al., 2002; Carissimi et al., 2006; Charroux et al., 1999, 2000;
Gubitz et al., 2002; Liu et al., 1997; Pellizzoni et al., 2002a). The
SMN complex is an assemblyosome that is essential for the bio-
genesis of small nuclear ribonucleoprotein particles (snRNPs)
(Fischer et al., 1997; Meister et al., 2001; Pellizzoni et al.,
2002b; Yong et al., 2004). snRNPs are major components of
the spliceosome, the machinery that carries out pre-mRNA splic-
ing (Nilsen, 2003; Will and Luhrmann, 2001). Each of the spliceo-
somal snRNPs (except for U6 and U6atac) is comprised of one
snRNA (U1, U2, U4, U5, U11, U12, and U4atac) and a set of
seven common proteins called the Sm proteins, as well as one
or more proteins that are specific to each snRNA (Kambach
et al., 1999; Nilsen, 2003; Will and Luhrmann, 2001). The assem-
bly of heptameric Sm protein rings on snRNAs (Sm cores) isstrictly dependent on the SMN complex (Meister et al., 2001;
Pellizzoni et al., 2002b; Wan et al., 2005).
Genetic lesions in the SMN gene (SMN1) that result in func-
tional SMN protein deficiency are the cause of spinal muscular
atrophy (SMA) (Lefebvre et al., 1995), a common genetic motor
neuron degenerative disease and a leading genetic cause of
infant mortality (Cifuentes-Diaz et al., 2002; Iannaccone et al.,
2004; Talbot and Davies, 2001). A second copy of the gene,
SMN2, contains a single nucleotide mutation in exon 7 that
results in frequent skipping of this exon and, consequently, low
levels of functional SMN protein (Lorson et al., 1999). Although
SMN is ubiquitously expressed in all tissues and is essential for
viability of all cells in diverse eukaryotic organisms (Paushkin
et al., 2002; Schrank et al., 1997; Wang and Dreyfuss, 2001),
the question of how reduction in SMN levels results in an appar-
ently cell-selective motor neuron phenotype remains unex-
plained (Monani, 2005). The SMN-dependent Sm core assembly
reaction can be studied in cell extracts, and the amount of Sm
core assembly on the snRNAs corresponds directly to the
amount of SMN protein and can be modulated by the other com-
ponents of the SMN complex (Battle et al., 2006b; Feng et al.,
2005; Wan et al., 2005). Indeed, extracts of SMA patient cells
have a lower snRNP assembly capacity, corresponding to the
lower amount of SMN protein they contain (Wan et al., 2005).
These and other findings indicate that the deficiency in the activ-
ity of the SMN complex in snRNP assembly is relevant to the
pathogenesis of SMA (Winkler et al., 2005). Several other func-
tions for the SMN complex in RNA metabolism have been sug-
gested, including functions in transcription (Pellizzoni et al.,
2001b), pre-mRNA splicing (Fischer et al., 1997; Pellizzoni
et al., 1998), the biogenesis of small nucleolar RNPs (snoRNPs)
(Charroux et al., 2000; Pellizzoni et al., 2001a; Whitehead et al.,
2002), and axonal RNA transport (Jablonka et al., 2004; Pagliar-
dini et al., 2000; Rossoll et al., 2003; Zhang et al., 2003), but these
remain uncharacterized.
The studies described here were initiated to determine what
effect a deficiency in SMN, and hence in the capacity of cells to
produce snRNPs, has on the steady-state levels of spliceoso-
mal snRNPs. We quantitated snRNAs in cell lines with reduc-
tions in SMN levels and an SMA mouse model, an SMN-defi-
cient organism. Unexpectedly, we found that SMN deficiency
does not cause a uniform reduction in snRNPs but rather hasCell 133, 585–600, May 16, 2008 ª2008 Elsevier Inc. 585
Figure 1. Severe Reduction of SMN in HeLa Cells Causes a Strong Decrease in snRNPs
(A) Schematic representation of the RRL.TetO-H1.SMNi.PGK.puro lentiviral vector in its proviral form. The U3 region is deleted in both LTRs (SIN, self inactivating;
Y, packaging signal; RRE, REV-responsive element; PPT, central poly-purine tract; tetO-H1, tetracycline inducible H1 promoter; PGK, phosphoglycerol kinase
promoter; Puro, puromycin resistance gene; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element).
(B) Total protein extracts were prepared from HeLa T-REx cells stably expressing shRNAs against mouse SMN (Control) or human SMN (RNAi) without () or with
(+) doxycycline. SMN complex components were detected by quantitative western blot, using a-tubulin and Magoh as loading controls.
(C) Total RNA was isolated from control and RNAi HeLa T-REx cells without (15% SMN, blue columns) or with (5% SMN, red columns) doxycycline. snRNA levels
were quantitated by real-time RT-PCR. The snRNA levels of the SMN RNAi cells are plotted as % of control. Same RNAi and snRNA quantitation experiments
were done at least three times and one typical experiment is shown. 5S and 5.8S rRNAs levels were used to normalize the RNA input and produced very similar
results, therefore only 5S rRNA-normalized data are presented here and in all subsequent real-time RT-PCR measurements for snRNA. The error bars are
propagated between SMN and control RNAi samples using the formula: dðx=yÞ=ðx=yÞ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðdx=xÞ2 + ðdy=yÞ2
q
(d: SD; x: SMA; y: Cont).cell type- and snRNA-specific effects, resulting in profoundly
different repertoires of snRNPs compared to those that contain
normal SMN levels. In light of the alterations in the normal rep-
ertoire of the major constituents of the splicing machinery, we
used exon microarrays to examine in detail if any changes oc-
curred in the splicing patterns in several tissues of SMA mice
compared to their unaffected littermates. We show that splicing
defects occur in numerous mRNAs in multiple tissues of SMA
mice and conclude that SMN plays a key general role in RNA
processing. The observation that deficiency of the ubiquitously
expressed SMN results in cell type-specific splicing defects
provides a new perspective on SMA and a plausible explana-
tion for the selectivity of SMA pathogenesis.
RESULTS
Alterations in snRNA Levels in SMN-Deficient Cells
To study the effect of reduced levels of SMN on the amount of
snRNAs, we established an inducible RNAi system for regu-
lated knockdown of SMN. Short hairpin RNAs (shRNAs) specif-586 Cell 133, 585–600, May 16, 2008 ª2008 Elsevier Inc.ically targeting either the human or mouse SMN mRNAs under
the transcriptional control of a tetracycline-inducible H1 pro-
moter were constructed in a lentiviral vector (Figure 1A). The
two vectors were packaged into viral particles and used first
to transduce a HeLa cell line (T-REx) constitutively expressing
the tetracycline repressor (TR) protein. In this case, the nontar-
geting mouse SMN shRNA was used as the control. Binding of
doxycycline to the TR activates transcription of the shRNA,
resulting in RNAi, and the extent of SMN reduction depended
on the multiplicity of infection and on doxycycline concentration
and was determined by quantitative western blots. Reduction
of SMN level to 20% (Figure S1A available online) of control
had no effect on cell growth rate or morphology (data not
shown). SMN levels could be further reduced to 5% of nor-
mal, and the cells survived under these conditions for an addi-
tional 2–3 days before cell death was evident (data not shown).
The capacity of assembly of Sm cores on snRNAs was mea-
sured using a quantitative assay in cell extracts (Wan et al.,
2005), and it corresponded directly to the amount of SMN
protein (Figure S1A).
To determine the effect of the reduction in snRNP assembly
capacity on the steady-state level of snRNAs, we carried out
real-time RT-PCR measurements for each of the spliceosomal
snRNAs. Despite the strong reduction (almost 80%) in snRNP
assembly capacity, there was no significant change in snRNA
levels (Figure S1B). A further reduction in SMN levels, to 15%
or less of normal levels, was necessary to observe significant
changes in snRNA levels. Using western blots, we measured
the levels of all the major components of the SMN complex,
including SMN, the Gemins, and Unrip, as well as a-tubulin
and Magoh, which served as loading controls (Figure 1B). In ad-
dition to the strong reduction in SMN, a severe reduction was ob-
served also for Gemin8 (87% before and 94% after induction),
Gemin2 (58% before and 86% after induction), and Gemin3
(67% before and 75% after induction). In contrast, Gemin5,
Gemin4, and Unrip remained unchanged. The snRNP assembly
activity in these cells was also strongly reduced in close correla-
tion with the amount of SMN protein remaining in these cells after
RNAi induction (data not shown).
As shown in Figure 1C, in the absence of doxycycline and with
only 15% of SMN remaining, a moderate reduction in U4, U5,
U12, and U4atac snRNAs was observed. However, a more
severe decrease in SMN, to 5% of normal, resulted in a pro-
nounced reduction, albeit to different extents, of most of the
snRNAs except U2 and U6. A very similar profile was observed
measuring the snRNAs in mature snRNPs obtained by immuno-
precipitation with Y12, a monoclonal antibody against Sm pro-
teins (Figure S2). This is consistent with previous reports that
the pool of snRNAs outside of snRNPs is relatively very small,
as snRNAs that are not assembled with Sm cores are unstable
(Sauterer et al., 1988; Zieve et al., 1988). These observations
suggest that HeLa cells have a large excess capacity to produce
snRNPs over what they require for viability. Importantly, once the
level of SMN drops below a critical threshold (15%–20% of
normal in these cells), the cellular contents of snRNAs is altered,
but the change is not uniform as different snRNAs are affected to
different extents.
To determine if a similar change in snRNAs occurs upon SMN
deficiency in other cell types and species, we carried out similar
measurements in a mouse motor neuron-derived cell line (MN1).
MN1 cells were transduced with lentivirus expressing either the
shRNA targeting mSMN or the nontargeting hSMN as control.
Measurements of the amount of each of the snRNAs in MN1 cells
where SMN levels were reduced to less than 10% of normal
(Figure S3A) showed a small increase in U1 snRNA (16%) and
a large decrease in U11 snRNA (40%) compared to control (Fig-
ure S3B). Importantly, the changes in the profiles of snRNAs in
MN1 and in HeLa cells with a similar degree of SMN deficiency
were markedly different, indicating that SMN deficiency causes
cell type-specific alterations in the repertoire of snRNAs.
A Decrease in SMN Complex Proteins and snRNP
Assembly Capacity in SMA Mice
To assess whether the observations described above can be
extended to the level of an organism and their potential relevance
to SMA, we performed similar studies in tissues of SMN-deficient
mice. For this, we used a moderate SMA mouse model corre-
sponding to a type II SMA phenotype (Le et al., 2005), as theaffected animals survive for up to 14 days after birth, which
allows the collection of various tissues at different stages as
the disease progresses. Here, we used both 6-day-old mice, at
which time the phenotype begins to become evident, and
11-day-old mice representing an advanced stage of the disease.
Tissues harvested from homozygous mSmn/ SMA mouse lit-
termates and their unaffected heterozygous littermates at 6
(P6) and 11 days (P11) after birth were used for preparation of
whole-tissue extracts for western blot, measurement of snRNP
assembly activity, and isolation of total RNA for quantitative
RT-PCR.
As expected, the level of SMN was severely reduced to 15%
of control in both brain and kidney (Figure 2A). Consistent with
observations in other SMN deficiency systems (Wang and Drey-
fuss, 2001), Gemin2 also showed significant reduction in SMA
mice (55% in brain and 48% in kidney), and Gemin8 was
severely reduced to an extent similar to that of SMN in both brain
and kidney of SMA mice, indicating a key role for SMN in main-
taining the stability of the entire SMN complex. The extent of
reduction in the level of SMN and other SMN complex compo-
nents was very similar between P6 and P11 mice (data not
shown). snRNP assembly activity was measured in total tissue
extracts from brain and kidney in P6 and from brain, kidney, spi-
nal cord, and heart in P11 control and SMA mice. Considerable
levels of snRNP assembly activity were detected in tissue ex-
tracts from P6 mice, whereas extracts of tissues of P11 mice
had extremely low levels of activity, in accordance with the pre-
viously reported downregulation of SMN complex activity during
mouse development (Gabanella et al., 2005). In close parallel to
the reduction in SMN levels, snRNP assembly activity in SMA
mice was reduced by 75%–80% in brain and kidney of P6
mice compared to the unaffected controls (Figure 2B).
Tissue-Specific Alterations in snRNAs in SMA Mice
Total RNA isolated from brain of P6 mice and from brain, spinal
cord, kidney, heart, and skeletal muscle of P11 mice was used
for real-time RT-PCR measurements of snRNAs. Significant
changes in the stoichiometry of snRNAs were already apparent
in P6 SMA mice (Figure 3). Marked reductions in some of the
minor spliceosomal snRNAs in P11 SMA mice were detected,
including U11, U12, and U4atac, which were reduced by
30% to 60% in brain, spinal cord, and heart compared to
the corresponding unaffected controls (Figure 3). This reduction
in the minor (U12-dependent) spliceosomal pathway snRNAs is
tissue specific, as the same snRNAs in kidney and skeletal mus-
cle are relatively unaffected in the SMA mice (Figure 3). In addi-
tion, we note that the levels of some major spliceosomal
snRNAs, particularly U6 snRNA in heart, U2 and U6 snRNAs in
kidney, and U1, U2, U5, and U6 snRNAs in skeletal muscle of
SMA mice, were significantly increased compared to those of
control mice (Figure 3), while the levels of 5S and 5.8S rRNAs,
which were used as input normalization controls, were not signif-
icantly changed (data not shown). Recently, after submission of
this manuscript, Gabanella et al. have also reported a decrease
in some of the minor snRNAs in SMA mouse tissues (Gabanella
et al., 2007).
Similar results were obtained using limited primer extension,
an alternative method for measuring the amounts of RNA, whichCell 133, 585–600, May 16, 2008 ª2008 Elsevier Inc. 587
Figure 2. A Decrease in SMN Complex Proteins Results in Diminished snRNP Assembly Capacity in SMA Mice
(A) Total protein extracts were prepared from brain and kidney of P6 control and SMA mice. SMN and Gemin proteins were detected by quantitative western blot,
using a-tubulin and Magoh as loading controls.
(B) Total protein extracts were prepared as in (A) from P6 control (n = 2) and SMA (n = 3) mice and snRNP assembly capacities were examined with biotinylated
U4 snRNA. Data are presented after subtraction of the background signal relative to U4 DSm snRNA. SMN complex activities from various SMA extracts (red
columns) were quantitated in comparison to control extract (blue columns). Error bars indicate standard deviation (SD).also illustrated the very large difference in abundance of the
major and minor spliceosomal snRNAs. Shown in Figure S4,
the measurement of U1, U11, U12, and U4atac snRNAs from
brains of P11 control and SMA mice indicated a 25%–35%
reduction in the levels of U11, U12, and U4atac snRNAs in
SMA mice, while U1 snRNA remained unchanged, consistent
with the real-time RT-PCR data described above.
Widespread Splicing Perturbations in Tissues
of SMN-Deficient Mice
Although the alterations in the normal repertoire of snRNAs in
SMN-deficient cells and in SMA mouse tissues were remarkable,
they did not appear to cause a catastrophic collapse of splicing
because, except for motor neurons, there was no evidence of cell
death. We therefore used the high resolution afforded by exon
microarrays to ask if there are any changes in splicing in SMA
compared to control mice. To do so, total RNA from three tis-
sues, spinal cord, brain, and kidney of three SMA mice and three
unaffected littermates, each prepared and processed sepa-
rately, were analyzed using the Affymetrix mouse exon 1.0 ST mi-
croarray. Among the 266,200 probe sets supported by putative
full-length mRNA, around 200,000 probe sets with significant
signals above background and representing exons of 20,000
out of 30,000 genes in the mouse genome (Waterston et al.,
2002) were included in the analysis. With a false discovery rate
(FDR) set at less than 0.1, 259, 73, and 633 genes from spinal588 Cell 133, 585–600, May 16, 2008 ª2008 Elsevier Inc.cord, brain, and kidney, respectively, were identified as having
potential splicing pattern changes (Table S1). The top 30 affected
genes from each tissue, ranked by absolute fold change of the
most affected exon of each transcript, are listed in Table 1. A rel-
atively small number of genes showedR1.5-fold change across
all exons (42, 0, and 264 genes from spinal cord, brain, and
kidney, respectively), indicating a much higher prevalence of
splicing changes compared to transcription changes (Table S2).
To assess the validity of the exon array data we performed
real-time RT-PCR on 31 genes (indicated by Q under Validation
& Characterization in Table 1), using exon junction-specific
primers and total RNA from the same control and SMA mice
used in the exon array. Except for one, where the signal with
the selected primers was too low for definitive measurement,
all confirmed the changes observed in the exon array, indicating
a validation rate of 97%.
In addition to measuring the amount of the exon in the tissue
from which the signal was originally selected for the purpose of
validation of the exon array data, we also determined the ex-
pression levels of the same exon in several other tissues, includ-
ing brain, spinal cord, muscle, heart, and kidney, in both the
control and SMA mice (Figure 4). These comprehensive mea-
surements were performed on eight of the genes listed in Table 1
(indicated by Q*), including three types of transporter proteins
(Abca8a, Kcng4, and Slc38a5), an extracellular matrix protein
(Col5a1), Uspl1, Agxt2l1, Hif3a, and Chodl. Importantly, these
Figure 3. A Decrease in SMN Complex Proteins Results in Tissue- and snRNP-Specific Reduction of snRNAs in SMA Mice
Total RNA was purified from brain of P6 control (n = 2) and SMA (n = 3) mice and brain, spinal cord, heart, skeletal muscle, and kidney of P11 control (n = 4) and
SMA (n = 3) mice. Real-time RT-PCR was performed to determine snRNA levels in each tissue. The relative amount of each snRNA in SMA mice tissues is
plotted as % of the controls. Error bars were calculated as in Figure 1C (*p < 0.01).measurements revealed a wide variation in the levels of these
exons in different tissues, indicating that the alterations in splicing
are tissue specific.
Figure 5 presents a summary of the exon array data for seven
of these genes and indicates several additional validation exper-
iments performed in the control and SMA mice. The height of the
bars indicates the fold change between SMA and control for the
probe sets representing each of the exons. The signal intensity
for each of these is shown in Figure S5. The small error bars re-
flect the low variability among the three control and the three
SMA mice used in the exon array experiments. Importantly,
these measurements indicated that both transcript- and tissue-
specific alterations in splicing occurred upon SMN deficiency.
To further validate and characterize the specific changes in the
transcripts, we performed high-throughput (HT) RT-PCR and an-
alyzed the products by high-resolution capillary electrophoresis
(Klinck et al., 2008). This large-scale analysis, consisting of more
than 4000 RT-PCR reactions in pairs of control and SMA, sur-
veyed 22 of the genes in Table 1 (indicated as R). All the data
of these experiments, including the sequences and locations of
primers used for the HT RT-PCR, the electrophoregrams, the
sizes and molarities of the products, and their positions on the
gene maps, are accessible online (see Experimental Proce-
dures). Because of space limitations, only a few representative
examples are presented here. The locations of specific changesobserved in some of these genes are indicated in Figure 5
(brackets labeled by R), and electrophoregrams of four pairs of
RT-PCR reactions are shown in Figure 6. These data revealed
numerous perturbations in the normal transcriptome. At least
17 of the examined genes (77%) contained changes predicted
by the exon array data, but a considerable number of additional
changes were documented. In some cases, the changes could
be explained as alternative splicing where the ratio of two spliced
isoforms is altered; however many others suggest aberrant splic-
ing with isoforms present in SMA mice that are not found in the
unaffected control littermates and often do not correspond to
a previously reported spliced isoform or are outright defective
as they produce a transcript that does not conform to normal
splicing sites.
Examples of some of the many striking cases of specific alter-
native splicing changes and aberrant splicing events detected in
the SMA mice are presented in Figure 6. The electrophoregrams
illustrate several types of transcript changes in different tissues
of the SMA mice, including changes in relative amounts of two
likely alternatively spliced exons (Agxt2l1 and Lrdd), changes in
the amount of several exons in the same transcript (Abca8a),
and an example of aberrant splicing (Hif3a). Another two cases
of aberrant splicing events were shown in Figures 5 and S6,
where aberrant splicing products were detected by RT-PCR
and then sequenced, and their amounts were measured byCell 133, 585–600, May 16, 2008 ª2008 Elsevier Inc. 589
Table 1. Top 30 Genes from Spinal Cord, Brain, and Kidney with One or More Exons Affected in SMA Mice
Accession
Number
Gene Symbol //
Description
Biological Process
or Molecular
Function
Fold-Change
of the Most
Affected Exon
Fold -Change
at Transcript
Level
Total
Affected
Exons
(R1.5-fold)
Total
Exons
Validation &
Characterization
Spinal Cord
NM_183187 BC055107 // cDNA sequence
BC055107
17.08 6.82 4 4 Q
NM_009928 Col15a1 // procollagen,
type XV
Structural molecule
activity (extracellular
matrix)
12.67 3.52 15 40 Q
NM_001013378 Uspl1 // ubiquitin-specific
peptidase like 1
Ubiquitin-dependent
protein
catabolic process
10.61 1.68 1 10 Q*, R , & S
NM_009930 Col3a1 // procollagen,
type III, alpha 1
Structural molecule
activity (extracellular
matrix)
10.59 3.13 28 51 Q
NM_010220 Fkbp5 // FK506 binding
protein 5
Protein folding 9.96 4.30 9 10 Q
NM_009864 Cdh1 // cadherin 1 cCell adhesion 8.50 2.34 7 16
NM_008608 Mmp14 // matrix
metallopeptidase 14
(membrane-inserted)
Peptidoglycan
metabolic
process (extracellular
matrix)
8.50 2.62 7 10
NM_028283 Uaca // uveal
autoantigen with coiled-coil
domains and ankyrin repeats
DNA damage
response, signal
transduction
8.10 2.22 7 19 Q, R*, & S
NM_010729 Loxl1 // lysyl
oxidase-like 1
Protein modification
process
7.94 2.40 4 7 R
NM_181277 Col14a1 // procollagen,
type XIV, alpha 1
Structural molecule
activity (extracellular
matrix)
7.93 2.74 18 48 R
NM_139134 Chodl // chondrolectin Muscle development 7.93 5.00 6 6 Q*
NM_015784 Postn // periostin,
osteoblast-specific factor
Cell adhesion
(extracellular matrix)
7.84 2.53 6 22 R
NM_145150 Prc1 // protein
regulator of cytokinesis 1
Cytokinesis 7.68 2.09 3 14 R
NM_172479 Slc38a5 // solute
carrier family 38, member 5
Transport 7.60 2.96 9 16 Q* & R
NM_029947 Prdm8 // PR domain
containing 8
Transcription 7.09 1.21 1 4
NM_153145 Abca8a // ATP-binding cassette,
subfamily A (ABC1), member 8a
Transport 7.07 2.68 15 38 Q* & R
NM_172791 Pla2g3 // phospholipase A2,
group III
Phospholipid
metabolic process
6.87 2.47 3 7
NM_008489 Lbp // lipopolysaccharide
binding protein
Transport 6.81 2.23 4 15
NM_007585 Anxa2 // annexin A2 Angiogenesis 6.79 2.52 10 13
NM_016868 Hif3a // hypoxia-inducible
factor 3, alpha subunit
Response to hypoxia 6.71 2.09 2 15 Q*, R, & S
NM_025734 Kcng4 // potassium
voltage-gated channel,
subfamily G, member 4
Transport 6.71 2.34 3 3 Q*
NM_026043 Rnpc3 // RNA-binding region
(RNP1, RRM) containing 3
RNA splicing 6.51 1.67 1 15590 Cell 133, 585–600, May 16, 2008 ª2008 Elsevier Inc.
Table 1. Continued
Accession
Number
Gene Symbol //
Description
Biological Process
or Molecular
Function
Fold-Change
of the Most
Affected Exon
Fold -Change
at Transcript
Level
Total
Affected
Exons
(R1.5-fold)
Total
Exons
Validation &
Characterization
NM_172617 Zfp523 // zinc
finger protein 523
Transcription 6.23 1.68 3 15
NM_172498 Ptk2b // PTK2 protein
tyrosine kinase 2 beta
Protein amino
acid phosphorylation
6.21 1.69 6 30
NM_007730 Col12a1 // procollagen,
type XII, alpha 1
Structural molecule
activity (extracellular
matrix)
6.17 2.29 30 66
NM_007669 Cdkn1a // cyclin-dependent
kinase inhibitor 1A (P21)
Regulation of
progression
through cell cycle
6.11 3.20 2 3
NM_013691 Thbs3 // thrombospondin 3 Cell adhesion 5.83 1.48 3 23
NM_022654 Lrdd // leucine-rich
and death domain containing
Apoptosis 5.73 1.96 7 15 R
NM_015734 Col5a1 // procollagen, type V,
alpha 1
Structural molecule
activity (extracellular
matrix)
5.70 1.99 10 66 Q*, R*, & S
NM_007742 Col1a1 // procollagen, type I,
alpha 1
Structural molecule
activity (extracellular
matrix)
5.55 3.07 22 51 Q
Brain
NM_030675 Krit1 // KRIT1, ankyrin
repeat containing
Signal transduction 12.19 1.26 1 17 ND
NM_011420 Smn1 // survival
motor neuron 1
Spliceosome
assembly
9.89 3.43 4 9
NM_027907 Agxt2l1 // alanine-glyoxylate
aminotransferase 2-like 1
Metabolism 7.17 2.84 5 13 Q* & R*
NM_011623 Top2a // topoisomerase (DNA) II
alpha
DNA metabolic
process
7.15 2.62 6 36 Q
NM_139206 Centd3 // centaurin, delta 3 Signal transduction 5.33 1.31 2 32 Q
NM_009791 Aspm // asp (abnormal
spindle)-like, microcephaly
associated (Drosophila)
Cell cycle 5.07 1.58 2 28 Q
NM_001013378 Uspl1 // ubiquitin-specific
peptidase like 1
Ubiquitin-dependent
protein
catabolic process
4.82 1.48 2 10 Q* & R*& S
NM_001013026 Ttf2 // transcription
termination factor, RNA
polymerase II
Transcription 4.23 1.17 2 23
NM_172479 Slc38a5 // solute
carrier family 38, member 5
Transport 4.10 2.01 5 16 Q*
NM_172379 AA536717 // expressed
sequence AA536717
3.96 1.08 1 7
NM_011360 Sgce // sarcoglycan, epsilon Cell-matrix adhesion 3.94 1.19 1 11
NM_009930 Col3a1 // procollagen, type III,
alpha 1
Structural molecule
activity (extracellular
matrix)
3.80 1.45 3 51 Q
NM_011403 Slc4a1 // solute
carrier family 4 (anion
exchanger), member 1
Transport 3.80 1.12 2 20 R
NM_025352 Uqcrq // ubiquinol-cytochrome c
reductase, complex III subunit VII
Electron transport 3.75 1.34 1 2
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Table 1. Continued
Accession
Number
Gene Symbol //
Description
Biological Process
or Molecular
Function
Fold-Change
of the Most
Affected Exon
Fold -Change
at Transcript
Level
Total
Affected
Exons
(R1.5-fold)
Total
Exons
Validation &
Characterization
NM_025565 Spc25 // SPC25, NDC80
kinetochore complex
component, homolog
(S. cerevisiae)
Cell cycle 3.60 1.05 1 6
NM_177049 Jph4 // junctophilin 4 Microsome (unknown
function)
3.45 1.08 1 6
NM_026539 Chd1l // chromodomain
helicase DNA-binding
protein 1-like
Nucleic acid binding 3.10 1.21 1 23
NM_172274 5730509K17Rik // RIKEN cDNA
5730509K17 gene
3.10 1.05 1 40
NM_011984 Homer3 // homer
homolog 3 (Drosophila)
Protein binding 2.72 1.18 1 10
NM_178227 Scn3b // sodium
channel, voltage-gated,
type III, beta
Transport 2.66 1.12 1 5
NM_026622 3110057O12Rik // RIKEN cDNA
3110057O12 gene
2.58 1.01 1 12
NM_146067 C530044N13Rik // RIKEN cDNA
C530044N13 gene
2.39 1.27 1 4
NM_013697 Ttr // transthyretin Thyroid hormone
generation
2.37 1.08 1 4
NM_138672 Stab1 // stabilin 1 Inflammatory
response
2.30 1.48 11 69 Q
NM_013869 Tnfrsf19 // tumor
necrosis factor receptor
superfamily, member 19
Apoptosis 2.16 1.08 2 10
NM_133817 Zfp451 // zinc
finger protein 451
Transcription 2.13 1.20 1 15
NM_177236 Atp2b3 // ATPase, Ca2+
transporting, plasma
membrane 3
Transport 2.12 1.07 1 21
NM_021501 Pias4 // protein
inhibitor of activated STAT 4
Nucleic acid binding 2.06 1.11 1 11
NM_007730 Col12a1 // procollagen, type
XII, alpha 1
Structural molecule
activity (extracellular
matrix)
2.02 1.50 2 66 Q
NM_172465 Zdhhc9 // zinc
finger, DHHC domain
containing 9
Zinc ion binding 2.01 1.12 1 10
Kidney
NM_010009 Cyp27b1 // cytochrome
P450, family 27, subfamily
b, polypeptide 1
Electron transport 54.59 22.25 8 9 Q
NM_010369 Gypa // glycophorin A Cytoskeletal
anchoring
12.61 3.65 2 8 Q & R
NM_145932 Osta // organic
solute transporter alpha
Transport 12.10 7.21 8 9
NM_147218 Abca6 // ATP-binding cassette,
subfamily A (ABC1), member 6
Transport 11.72 3.70 23 39 Q & R
NM_153145 Abca8a // ATP-binding cassette,
subfamily A (ABC1), member 8a
Transport 11.49 5.31 28 38 Q* & R*592 Cell 133, 585–600, May 16, 2008 ª2008 Elsevier Inc.
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NM_016868 Hif3a // hypoxia-inducible
factor 3, alpha subunit
Response to hypoxia 11.20 2.80 7 15 Q*, R*, & S
NM_007822 Cyp4a14 // cytochrome P450,
family 4, subfamily a,
polypeptide 14
Electron transport 11.06 4.23 10 12
NM_011420 Smn1 // survival
motor neuron 1
Spliceosome
assembly
10.88 2.85 2 9
NM_021456 Ces1 // carboxylesterase 1 Metabolism 9.43 3.58 7 14
NM_172399 A930038C07Rik // RIKEN cDNA
A930038C07 gene
8.85 2.85 4 4
NM_178259 Abca13 // ATP-binding cassette,
subfamily A (ABC1), member 13
Transport 8.47 2.91 27 62 Q & R
NM_138595 Gldc // glycine decarboxylase Metabolism 7.93 4.17 24 25
NM_173767 Insc // inscuteable
homolog (Drosophila)
Multicellular
organismal
development
7.78 2.33 5 10
NM_010778 Cd46 // CD46 antigen,
complement regulatory protein
Single fertilization 7.17 2.26 5 11 Q & R
NM_029939 C330001K17Rik // RIKEN cDNA
C330001K17 gene
7.13 1.48 2 13
NM_010220 Fkbp5 // FK506-binding protein 5 Protein folding 7.08 4.58 10 10 Q
NM_010061 Dnase1 // deoxyribonuclease I DNA catabolic
process
7.06 3.25 9 9
NM_181318 Rasgef1b // RasGEF
domain family, member 1B
Signal transduction 6.83 4.14 14 14
NM_172466 Adamts18 // a disintegrin-like
and metallopeptidase
(reprolysin type) with
thrombospondin type
1 motif, 18
Proteolysis 6.77 1.70 9 23
NM_008071 Gabrb3 // gamma-aminobutyric
acid (GABA-A) receptor,
subunit beta 3
transport -6.44 -3.32 5 10
NM_025685 Col27a1 // procollagen, type
XXVII, alpha 1
Structural molecule
activity (extracellular
matrix)
6.33 1.55 9 61 Q
NM_023617 Aox3 // aldehyde
oxidase 3
Electron transport 6.25 1.57 3 35
NM_008341 Igfbp1 // insulin-like
growth factor binding
protein 1
Regulation of cell
growth
6.24 3.07 2 3
NM_016771 Sult1d1 // sulfotransferase
family 1D, member 1
Sulfate assimilation 6.20 3.25 8 8
NM_021381 Prokr1 // prokineticin
receptor 1
Signal transduction 6.17 2.64 2 3
NM_029415 Slc10a6 // solute carrier family
10 (sodium/bile acid
cotransporter family), member 6
Transport 5.97 1.82 4 6
NM_177200 Svopl // SV2-related protein
homolog (rat)-like
Transport 5.31 2.52 10 16
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NM_028981 Cacna1d // calcium
channel, voltage-dependent,
L type, alpha 1D subunit
Transport 5.21 1.85 15 48 Q
NM_207216 Ugt3a1 // UDP glycosyltransferases
3 family, polypeptide A1
Metabolism 5.02 1.92 5 7
NM_013454 Abca1 // ATP-binding cassette,
subfamily A (ABC1), member 1
Transport 5.02 2.41 25 50
Q: real-time RT-PCR; R: RT-PCR; S: Sequencing; ND: Not determined; *: detailed data shown in Figures 4, 5, or 6.real-time RT-PCR in control and SMA mice. For Col5a1, the ab-
errant transcript, which was only detectable in the SMA mice,
skipped the last 223 nt of exon 62 and first 21 nt of exon 63, cre-
ating premature termination codons (PTCs) in the new open
reading frame (ORF) (Figures 5 and S6A). Similarly, an aberrant
transcript from Uaca in which exon 3 is skipped and PTCs
were generated in the ORF was detected in SMA mice (Figures
5 and S6B). The generation of PTCs explains why the relative
amount of the aberrant transcripts is, in many cases, relatively
low and difficult to detect. The reduction in the level of the normal
transcript, for example, 50% for Col5a1, is consistent with
a scenario in which about half of the pre-mRNA is aberrantly
spliced but only a fraction of that is detectable because it is
eliminated by nonsense-mediated decay (NMD).
Functional annotations of the most affected genes in the three
tissues, using Database for Annotation, Visualization and Inte-
grated Discovery (DAVID), indicated that a wide diversity of
genes were affected and revealed an over-representation of
genes expressing transporter and extracellular matrix proteins.
The functional annotations of the 30 most highly affected genes
for each of the tissues are listed in Table 1. Although the number
of affected genes common to all three tissues is small (only two
genes), transcripts of transporter and extracellular matrix genes
are particularly affected in all three tissues. These classes of
genes have particularly large numbers of exons. In fact, among
the 259, 73, and 633 affected genes in SMA mice spinal cord,
brain, and kidney, the median number of exons in the affected
transcripts is 14, 10, and 12, respectively. In the mouse genome,
the median number of exons per transcript is only 6 (Waterston
et al., 2002). This suggests that pre-mRNAs with more introns
(exons) to splice are more vulnerable to splicing changes in
SMA mice.
DISCUSSION
Our findings here demonstrate that SMN deficiency causes pro-
found changes in cellular RNA metabolism. It alters the repertoire
of snRNAs and perturbs pre-mRNA splicing, leading to numer-
ous splicing defects. The defects are widespread and cell type
specific, affecting mRNAs of functionally diverse genes. These
surprising discoveries place the SMN complex, the essential594 Cell 133, 585–600, May 16, 2008 ª2008 Elsevier Inc.machinery for the biogenesis of snRNPs, as a major factor in
splicing regulation. Furthermore, they provide an example of how
a deficiency in a ubiquitous protein can result in tissue-specific
changes and cast a new light on the pathophysiology of SMA.
A large degree of SMN decrease (>80%) is required to cause
a significant change in the levels of snRNAs or cause cell death in
cultured cells, suggesting that cells normally contain a large
excess capacity of SMN complex to maintain their normal inven-
tory of snRNAs. While a reduction in the amount of snRNAs upon
decrease in SMN was not unexpected, its nonuniformity across
different snRNAs and its cell type specificity were unanticipated.
Immunoprecipitation of snRNPs from total extract, which could
be reliably performed from tissue cultured cells but not from
mouse tissues, showed a similar stoichiometry for snRNAs in
total RNA preparations and in snRNPs, consistent with previous
observations that the pool of unassembled snRNAs is very small,
and suggest that the cells have a similarly altered repertoire of
snRNPs. The biogenesis of snRNPs is a highly regulated and
intricate stepwise process, and the SMN complex is essential
for the key step of the Sm core assembly on which all sub-
sequent steps depend (Battle et al., 2006a; Massenet et al.,
2002; Narayanan et al., 2002; Will and Luhrmann, 2001). The
steady-state level of each snRNA is determined by the gene
copy number of that snRNA and by many other factors, including
its rate of transcription, processing, transport, assembly, modifi-
cations, and turnover, as well as availability of both the common
and snRNA-specific proteins. Many of these factors could be
regulated differently in different cell types and at various stages
of development. It is also possible that the SMN complex, in ad-
dition to its direct function in Sm core assembly, also plays a role
in other steps of snRNP biogenesis and snRNA metabolism.
Little is known about the regulation of the biogenesis and turn-
over of snRNPs in different tissues, and it will be of interest to
study these processes under both normal and SMN-deficient
conditions.
The splicing changes we observe are widespread, affecting
hundreds of genes in different tissues of SMN-deficient mice. Dif-
ferent splicing changes occur in different tissues, but the same
splicing changes are observed independently in the same tissue
in each of the individual SMN-deficient mice. The very high con-
firmation rate of changes identified by the exon array and the
Figure 4. Confirmation of Predicted Changes in Exon Expression Levels
Exon junction-specific primer/probe sets (indicated in parenthesis after the gene name) were used to measure affected exons from eight genes by real-time
RT-PCR, using total RNA prepared from brain, spinal cord, muscle, heart, and kidney tissues of control (n = 4) and SMA (n = 3) mice. Total RNA inputs were
normalized by GAPDH mRNA levels. Exon levels of SMA samples are plotted as % of controls. The affected exons and tissues predicted by exon arrays are
highlighted in red. Error bars were calculated as in Figure 1C (*p < 0.05).validation of numerous specific cases by RT-PCR attest to the
high reliability of the data set we obtained. Using the stringent cri-
teria we applied to selection of the affected transcripts, only
a fraction of genes for which robust signals were obtained
showed splicing perturbations (<2% of genes). However, the
number of affected transcripts is likely to be much higher be-
cause the signals for any given exon represent the average for
all transcripts in the tissue. To be detected, a significant change
in the signal of an exon would have to occur in a large fraction of
the transcripts that contain it. Thus, an aberrant splicing of an
exon could be severe in some or even all of the transcripts that
contain it in a specific cell population and may not be detectable
in the total tissue sample. It is possible that a specific splicing de-
fect that is detrimental to motor neurons occurs but was not de-
tected in the total RNA sample from spinal cord. The lack of an
effect on the level of the majority of the transcripts nevertheless
indicates that general Pol II transcription and mRNA turnover
have not been significantly affected, consistent with cDNA ex-
pression microarray experiments using different SMA mouse
models with milder phenotypes (Balabanian et al., 2007; Olaso
et al., 2006). In many cases, the aberrant splicing generates anmRNA that contains a PTC. These transcripts are present only
at very low levels probably because they were subject to non-
sense-mediated decay.
Importantly, although some of the changes we observe in spe-
cific exons may correspond to shifts in alternative splicing pat-
terns, most of them do not; they are abnormal RNA processing
events that give rise to aberrant splicing products, which nor-
mally are not produced. We conclude this because many of
the exons that are significantly changed in the SMA mice, for
example the exons skipped in Hif3a (Figure 6), Col5a1, and
Uaca (Figure S6), are unaffected in the control mice and have
not been reported to be alternatively spliced. In addition, it is
not possible to distinguish based on the available data whether
all copies of an affected transcript where more than one exon
is aberrantly spliced have the same defect or whether the defects
are distributed among many different transcripts.
The mechanistic basis for the widespread splicing defects
caused by changes in the levels of SMN, hitherto known to func-
tion in the biogenesis of snRNPs, remains to be determined.
Splicing is dependent both on snRNPs and RNA-binding pro-
teins (hnRNPs and SR proteins). Knockdowns of mRNACell 133, 585–600, May 16, 2008 ª2008 Elsevier Inc. 595
Figure 5. Summary of Exon Array Data and Validation for Representative Genes
Fold-changes of probe sets detecting exon levels (SMA versus control) are shown on top of the corresponding exon of each gene structure. Note some exons are
measured by multiple probesets, while some do not have any targeting probe sets and are not shown in the gene structure. RT-PCR (R), real-time RT-PCR (Q),
and sequencing (S) validation reactions are indicated below the gene structure.processing factors, including spliceosomal protein components,
have been shown to have differential effects on the splicing of
a subset of pre-mRNAs in yeast (Clark et al., 2002; Pleiss
et al., 2007) and on alternative splicing of a few pre-mRNAs in
Drosophila (Park et al., 2004). Rather than depletion of an individ-
ual splicing factor, deficiency in SMN, which is not itself a compo-
nent of the splicing machinery, causes changes in multiple
snRNAs, leading to an altered snRNP repertoire. Despite this,596 Cell 133, 585–600, May 16, 2008 ª2008 Elsevier Inc.there is no reason to believe that the composition of snRNPs
within each spliceosome is altered in SMN-deficient cells. Impor-
tantly, while changes in the stoichiometry of snRNPs have not
been previously associated with global regulation or defects in
splicing, our observations merit consideration of such a link.
Like the major spliceosomal snRNPs, many of the hnRNP and
SR proteins that play a role in splicing are extremely abundant
and present in vast excess over their high-affinity binding sites
Figure 6. Confirmation of Expression and Splicing Pattern Changes by HT RT-PCR Reactions
HT RT-PCR reactions characterizing expression and splicing pattern changes of four genes are shown as electrophoregrams. Sizes and molarities of RT-PCR
products are listed above the electrophoregrams, and the sizes and migrating times of markers can be found below. Blue and red arrows indicate PCR products
representing splicing pattern changes in control and SMA mice, respectively. Relevant PCR products (peaks) are also illustrated by schematic gene structures
with predicted sizes. Solid black circles above the exon structures represent primer binding regions.Cell 133, 585–600, May 16, 2008 ª2008 Elsevier Inc. 597
on pre-mRNAs (Dreyfuss et al., 1993, 2002), yet even moderate
changes in their relative stoichiometry have significant effects on
alternative splicing patterns (Black, 2003; Hou et al., 2002;
Kashima and Manley, 2003; Licatalosi and Darnell, 2006; Marti-
nez-Contreras et al., 2006; Paradis et al., 2007; Wang and Man-
ley, 1995; Zhu et al., 2001). The complexity of the network of
interactions among the snRNPs and between snRNPs and the
enormous assortment of splicing factors precludes meaningful
prediction of specific splicing outcomes based on a particular
snRNA repertoire, at this time. However, we suggest that a
change in the stoichiometry of snRNPs perturbs this network
and affects the efficiency, rate, and fidelity of spliceosome
assembly on different introns. Because each cell type has
a unique assortment of splicing factors and SMN deficiency
causes its snRNP repertoire to change in a unique way, the
resulting perturbations are distinct and give rise to cell type-
specific effects on splicing. We note, however, that alternative
mechanisms cannot be ruled out. For example, the SMN
complex could have an snRNA-independent effect on splicing,
as experiments with an SMN mutant in vitro have suggested
(Pellizzoni et al., 1998), or in other aspects of RNA metabolism.
Another possible snRNA-dependent scenario for the splicing
perturbations is that some unassembled snRNAs accumulate
in SMN-deficient cells, which might then sequester snRNP pro-
teins or other proteins required for splicing. The important con-
clusion nevertheless remains, that the stoichiometry of the major
constituents of the splicing machinery (the ‘‘snRNPertoire’’) is
altered and that transcripts reflecting a faulty splicing process
accumulate in SMN-deficient cells.
Further studies will be required to uncover the specific mecha-
nism at fault for particular transcripts out of the hundreds or thou-
sands that are affected. The splicing changes we observe in SMN
deficiency appear to reflect a general defect in splicing and do not
resemble the splicing changes that result from modulation of spe-
cific splicing factors (Black, 2003; Caceres et al., 1994; Licatalosi
and Darnell, 2006; Ule et al., 2005; Wang and Manley, 1995).
However, examination of the affected transcripts reveals several
striking features. Pre-mRNAs containing a large number of in-
trons are much more likely to suffer aberrant splicing, suggesting
that the likelihood of splicing defects increases with the number
of splicing events the transcript undergoes. We note, in addition,
that a considerable number of the aberrantly spliced transcripts
have more than one splicing abnormality (see Table 1). This
appears to exceed the probability of random events and sug-
gests that the affected transcripts have a specific susceptibility
to the suboptimal splicing machinery in SMN-deficient cells and
that a splicing defect in one intron may be propagated to other
introns in the same transcript. We suggest that having a large
number of introns makes a transcript more vulnerable to splicing
defects upon decreased SMN complex activity, presenting
a challenge to evolutionarily more advanced organisms possess-
ing many multi-intron genes. Classification of the aberrantly
spliced transcripts by gene ontology indicates that proteins of
diverse functions are affected and reveals a very high preponder-
ance of membrane transporters and extracellular matrix proteins
(Table 1). Further analysis of the affected transcripts will be
required to determine if there are sequence motifs common to
these RNAs that cause their splicing defects. Nevertheless, it is598 Cell 133, 585–600, May 16, 2008 ª2008 Elsevier Inc.apparent that many of the affected transcripts contain a large
number of introns that likely explain their susceptibility.
A new view of SMA emerges from these findings. The selective
degeneration of motor neurons is a characteristic feature of
SMA, and several potential explanations for this pathogenesis
have been suggested, including the possibility of a specific func-
tion for SMN in these cells (Monani, 2005). However, our findings
that SMN deficiency causes cell type-specific perturbations in
the composition of the major components of the spliceosome
and a defective transcriptome throughout all cells and tissues,
not only motor neurons, indicate that SMA is a general splicing
disease. An unanticipated alternative explanation for the mo-
tor-neuron selective phenotype in SMA may therefore be that
cell-specific factors that influence the relative abundance of indi-
vidual snRNPs, rather than a cell-specific function of SMN itself,
account for the cell-specific phenotype, but their effect is mani-
fested only when SMN, the common factor in the general path-
way, becomes limiting. The attrition of motor neurons may be
caused by one or more aberrant transcripts or by the cumulative
effect of many splicing defects. However, it now seems possible
that splicing defects in surrounding cells, such as those that
make up the matrix on which motor neurons depend, may be
the cause or a contributing factor to the demise of the motor neu-
rons. As the severity of SMA is directly correlated with the degree
of SMN deficiency, it is likely that even moderate reductions in
SMN levels alter the snRNP repertoire and perturb splicing,
albeit more subtly than those we have studied here. Together,
the observations we describe here establish a key role for the
SMN complex in gene regulation, particularly in the maintenance
of splicing machinery.
EXPERIMENTAL PROCEDURES
Harvesting of Mouse Tissues
All experiments with mice were carried out in accordance with the NIH Guide
for the Care and Use of Laboratory Animals and were approved by the Institu-
tional Animal Care and Use Committee (IACUC Protocol # 800714). The mice
were anesthetized with isoflurane and then sacrificed at the indicated age by
cervical dislocation. Tissues were collected by manual dissection and either
used immediately or frozen in liquid nitrogen and stored at 80C until further
processing.
Reverse Transcription and Real-Time PCR Measurement of snRNAs
Total RNA was extracted from culture cells and tissues using mirVana miRNA
isolation kit (Ambion). 5S, 5.8S rRNA, and snRNA-specific primers were used
to generate cDNA using Advantage RT-for-PCR kit (Clontech). One hundred
nanograms (or 375 ng for minor snRNAs) of total RNA was utilized as template
in a 20 ml reaction. One percent of the cDNA was used for each real-time PCR
reaction.
Real-time PCR experiments for snRNA quantification were carried out on an
Applied Biosystems 7500 fast real-time PCR system using SYBR Green I dye
chemistry. The same reverse primers were used in both RT and real-time PCR.
Each snRNA from mouse tissue or cell samples was measured in triplicates.
Absolute quantification was performed using ABI 7500 Fast System Detection
Software. Details of all primers and probes are in Table S3.
Exon Microarray Target Preparation, Array Hybridization,
and Data Analysis
Biotinylated sense-strand DNA targets were prepared using the Affymetrix
GeneChip Whole Transcript (WT) Sense Target Labeling Assay according
to the manufacturer’s directions. One microgram of total RNA from normal
(n = 3) and SMA (n = 3) mouse spinal cord, brain, and kidney was used as input
for the first round of amplification. Ten micrograms of the resulting cRNA was
used to proceed to the second round of amplification. A hybridization cocktail
including 5.5 mg of fragmented, end-labeled ssDNA was applied to GeneChip
Mouse Exon 1.0 ST arrays. Hybridization was performed using F450-001
fluidics wash and stain script on the Affymetrix GeneChip Fluidics Station
450. Arrays were scanned using the Affymetrix GCS 3000 7G and GeneChip
Operating Software (GCOS) to produce .CEL intensity files.
Probeset intensities were calculated from the CEL files of the 18 samples us-
ing the RMA algorithm with default settings at both the gene level and the pro-
beset level in Partek Genomic Suite 6.3, using the core probe sets as defined
by Affymetrix. Probesets with maximum RMA intensity of 3 across all samples
were excluded to eliminate probesets with low expression levels. Alternative
splicing multiway ANOVA was applied using Partek defaults with terms (probe-
set ID and group) reflecting not only experimental conditions but also terms
that allow detection of alternative splicing events that differ between the sam-
ple groups. FDR was calculated and genes with FDR < 0.1 for differential ex-
pression or alternative splicing were considered. ANOVA was also applied at
the exon level to determine differential expression of exons not grouped by
transcript. Functional annotation was performed using DAVID 2007 (http://
david.abcc.ncifcrf.gov/home.jsp). The data were analyzed comparing the
proportions of genes with altered splicing against the total genes expressed
above background on the microarray.
HT RT-PCR
HT RT-PCR, capillary electrophoresis, and data analysis were performed as
previously described (Klinck et al., 2008). PCR primer locations, sequences,
and electrophoregrams of all reactions are available at http://palace.lgfus.
ca/login, using dreyfuss_public and public for username and password, re-
spectively, or upon request from the authors at http://www.med.upenn.edu/
dreyfusslab.
ACCESSION NUMBERS
The exon array data can be accessed at NCBI Gene Expression Omnibus
repository (accession number GSE10599).
SUPPLEMENTAL DATA
Supplemental Data include Experimental Procedures, six figures, and three
tables and can be found with this article online at http://www.cell.com/cgi/
content/full/133/4/585/DC1/.
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